HOPIN
7.1.2021 13:32:26 CET | Business Wire | Press release
Hopin, a leading virtual events platform, announced today that it has acquired StreamYard, a live video streaming studio that allows content creators to produce professional-quality video streaming experiences. The purchase will allow Hopin to provide advanced video production features to Hopin event organizers. In addition to eventually integrating its features into the Hopin platform, StreamYard will continue to also offer its live streaming studio tools to independent content creators. Hopin will pay a total purchase consideration of $250 million to acquire StreamYard, comprised of cash and stock.
“When I founded Hopin, I wanted to replicate all the best aspects of physical events -- from one-on-one networking to exploring an expo -- and more. As Hopin became the go-to virtual venue for event organizers, the next product to add was professional-quality video production, so I’ve long had my eye on the advanced studio tools that StreamYard provides,” said Johnny Boufarhat, founder and CEO of Hopin. “StreamYard is the solution of choice for live streamers around the world because of its superior ease of use and great features. This acquisition fits in with our goal to build the best products that help people connect and communicate better through engaging online experiences. I can’t wait to make it available to all of our customers so they can uplevel their events and truly dazzle their attendees.”
“Live streamers love StreamYard for its ease of use, stability, and professional-quality streams and I am thrilled that we can now easily bring those three pillars to event organizers around the world,” said Geige Vandentop, co-founder and CEO, StreamYard. “We have been integrating with Hopin as a third-party broadcast solution for months and it just makes sense to officially join forces and combine our efforts. At StreamYard, we are now committed to serving the needs of content creators and event producers alike.”
StreamYard, based in Tualatin, Oregon, was founded in 2018 by Geige Vandentop and Dan Briggs. They were inspired by live streaming’s rapid growth in the gaming community, which ultimately allowed people to turn hobbies into careers. However, they recognized that live streaming production required expensive hardware and an understanding of complex technology, a considerable barrier for most businesses wanting to create compelling live content for their audiences. To solve this, they developed a streaming solution that was simple to use by anyone, but powerful enough to create professional-quality content. The two founders bootstrapped StreamYard and grew revenues to nearly $10 million in early 2020 before quickly hiring a team of 19 and reaching over $30 million in annual recurring revenue by year-end. Today, StreamYard serves over 100,000 paying customers, adding 10,000 paying customers per month, and powers millions of broadcasts every month with a diverse global user-base ranging from social media influencers to large corporations.
StreamYard is a cloud-based solution that works in any web browser to empower businesses, entertainers, hobbyists, nonprofits, and anyone with a message to create compelling live events for their audiences and simulcast live to a number of social channels, including YouTube, Facebook, LinkedIn, and Twitch. It allows creators to easily brand their broadcasts with themes, color schemes, overlays, backgrounds, logos, and even GIFs. They can also easily host up to ten live guests to interview at once, show on-screen comments from viewers, and add call-to-action interactions to increase conversions and sales.
Hopin and StreamYard will work together to help event organizers bring StreamYard’s compelling, engaging, and easy-to-use capabilities to their online gatherings. StreamYard will soon replace the Hopin Studio and power all Hopin Stages, with native integration expected in H1 2021. Hopin aims to accelerate StreamYard’s innovative product development, sales and marketing, and grow StreamYard’s enterprise customer base. Vandentop and Briggs will continue to oversee the StreamYard team of 19 employees, while joining Hopin to assist Boufarhat in building out the company’s overall vision as a one-stop-shop for the best video broadcasting services and virtual event experiences.
“Hopin is one of our most astounding growth stories; the team’s Series B in November was a momentous milestone in every respect, including for the fast-changing virtual events industry,” said Sonali De Rycker, partner at Accel. “And they’ve now acquired two companies—first Topi, and now StreamYard. To pull this off in the first year of operation is unprecedented. The combination with StreamYard is incredibly powerful and will further fuel Hopin’s trajectory as it charts the future of online experiences.”
Hopin continues to enjoy rapid growth and soaring demand since its launch in February 2020. It has scaled from 5,000 registered users and 1,800 organizations hosting events on the Hopin platform to more than 5 million users and over 100,000 organizations hosting events. Last year alone, the remote-first company grew from eight employees to nearly 300 across 38 countries. Hopin has raised over $170 million to date, most recently completing a $125 million Series B led by IVP and Tiger Global and joined by Coatue and DFJ Growth, along with Hopin’s returning investors Accel, Northzone, Salesforce Ventures, and Seedcamp.
About Hopin
Founded in 2019, Hopin is the first all-in-one live virtual events platform where attendees can learn, interact, and connect with people from anywhere in the world. With Hopin, you can create live virtual and hybrid events that are interactive and immersive. Whether you're hosting a live training workshop, bringing your company’s remote team together, or launching a full-scale annual conference, it’s easy to create an engaging event on Hopin for up to hundreds of thousands of people. Attendees can network one-on-one, break out into group sessions, watch keynote presentations, send chat messages and polls, and explore interactive expo areas. There’s also a virtual backstage for speakers and plenty of sponsorship opportunities. Hopin is a remote-first company based in London, with employees in 38 countries. Learn more at hopin.com .
About StreamYard
StreamYard provides a live video streaming studio that allows content creators to produce professional-quality streaming experiences. StreamYard’s cloud-based solution makes it easy to create graphically-rich branded experiences, host multiple guests at once, engage with viewers, and simulcast to multiple live streaming platforms, including YouTube, Facebook, LinkedIn, and Twitch. Founded in 2018, StreamYard is based in Tualatin, Oregon. For more information, visit streamyard.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005258/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer31.8.2026 12:00:00 CEST | Press release
Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). At IA2, ZIIHERA plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared with trastuzumab plus chemotherapy, meeting the remaining primary endpoint analysis of the study. IA2 also provided longer follow-up data for the TEVIMBRA plus ZIIHERA
GigaDevice Strengthens EMEA and Southeast Asia Market Reach Through Strategic Partnership with Rutronik31.8.2026 09:00:00 CEST | Press release
GigaDevice, a leading semiconductor company specializing in Flash memory, 32-bit microcontrollers (MCUs), sensors, and analog products, today announced a new strategic franchise partnership with Rutronik Elektronische Bauelemente GmbH, one of Europe’s leading broadline distributors of electronic components. The agreement covers EMEA and Southeast Asia, including India, and provides customers with broader access to GigaDevice’s comprehensive portfolio of microcontrollers, sensors, and power management solutions. The partnership further strengthens GigaDevice’s distribution network and local market presence across key regions. With its strong presence across Europe and growing coverage in Southeast Asia, Rutronik provides GigaDevice with an established channel supported by extensive market reach, technical expertise, and customer relationships. The collaboration will help expand access to GigaDevice’s embedded solutions across a broad range of applications and industries, including indus
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
